Identification | Back Directory | [Name]
1H-Indole-1-ethanol, 5-aMino-2-[1,1-diMethyl-2-(phenylMethoxy)ethyl]-6-fluoro-α-[(phenylMethoxy)Methyl]-, (αR)- | [CAS]
1294504-67-8 | [Synonyms]
Tezacaftor Intermediate (R)-1-[5-Amino-2-(2-benzyloxy-1,1-dimethyl-ethyl)-6-fluoro-indol-1-yl]-3-benzyloxy-propan-2-ol (2R)-1-[5-Amino-2-(2-benzyloxy-1,1-dimethyl-ethyl)-6-fluoro-indol-1-yl]-3-benzyloxy-propan-2-o (2R)-1-[5-Amino-2-(2-benzyloxy-1,1-dimethyl-ethyl)-6-fluoro-indol-1-yl]-3-benzyloxy-propan-2-ol (R)-1-(5-aMino-2-(1-(benzyloxy)-2-Methylpropan-2-yl)-6-fluoro-1H-indol-1-yl)-3-(benzyloxy)propan-2-ol (2R)-1-[5-amino-6-fluoro-2-(2-methyl-1-phenylmethoxypropan-2-yl)indol-1-yl]-3-phenylmethoxypropan-2-ol (2R)-1-{5-amino-2-[1-(benzyloxy)-2-methyl-2-propanyl]-6-fluoro-1H-indol-1-yl}-3-(benzyloxy)-2-propanol 1H-Indole-1-ethanol, 5-aMino-2-[1,1-diMethyl-2-(phenylMethoxy)ethyl]-6-fluoro-α-[(phenylMethoxy)Methyl]-, (αR)- 1H-Indole-1-ethanol, 5-aMino-2-[1,1-diMethyl-2-(phenylMethoxy)ethyl]-6-fluoro-α-[(phenylMethoxy)Methyl]-, (αR)-8 (2R)-1-{5-amino-2-[1-(benzyloxy)-2-methylpropan-2-yl]-6-fluoro-6,7-dihydro-1H-indol-1-yl}-3-(benzyloxy)propan-2-ol | [EINECS(EC#)]
811-584-9 | [Molecular Formula]
C29H33FN2O3 | [MDL Number]
MFCD23106326 | [MOL File]
1294504-67-8.mol | [Molecular Weight]
476.582 |
Chemical Properties | Back Directory | [Boiling point ]
648.5±55.0 °C(Predicted) | [density ]
1.16±0.1 g/cm3(Predicted) | [storage temp. ]
Hygroscopic, Refrigerator, under inert atmosphere | [solubility ]
DMSO (Slightly), Methanol (Very Slightly) | [form ]
Solid | [pka]
13.99±0.20(Predicted) | [color ]
Very Dark Grey | [InChIKey]
RABRVTLWYYBNAK-FKEMPHOKNA-N | [SMILES]
C(N1C2=C(C=C(N)C(F)=C2)C=C1C(C)(C)COCC1=CC=CC=C1)[C@@H](O)COCC1=CC=CC=C1 |&1:24,r| |
Hazard Information | Back Directory | [Uses]
(R)-1-(5-Amino-2-(1-(benzyloxy)-2-methylpropan-2-yl)-6-fluoro-1H-indol-1-yl)-3-(benzyloxy)propan-2-ol is a Tezacaftor (T321510) intermediate. Tezacaftor is used as a combination therapy with Ivacaftor for the treatment of patients with cystic fibrosis. |
|
|